Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-11-18 2:09 pm Purchase | 2022-11-08 | 13D | ARS Pharmaceuticals, Inc. SPRY | Lowenthal Richard E | 7,422,432 7.900% | 7,422,432 (New Position) | Filing History |
| 2022-11-18 1:58 pm Purchase | 2022-11-08 | 13D | ARS Pharmaceuticals, Inc. SPRY | Tanimoto Sarina | 6,265,170 6.700% | 6,265,170 (New Position) | Filing History |
| 2022-07-15 6:03 pm Purchase | 2022-07-13 | 13G | ARS Pharmaceuticals, Inc. SPRY | K2 PRINCIPAL FUND L.P. | 1,906,618 5.410% | 1,906,618 (New Position) | Filing History |
| 2022-02-14 4:33 pm Sale | 2021-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY | Boxer Capital LLC | 0 0.000% | -1,675,377 (Position Closed) | Filing History |
| 2022-02-14 4:11 pm Unchanged | 2021-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY | RA Capital Management, L.P. | 1,742,186 4.970% | 0 (Unchanged) | Filing History |
| 2022-02-14 1:38 pm Sale | 2021-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY | EcoR1 Capital, LLC | 1,060,010 3.000% | -1,473,625 (-58.16%) | Filing History |
| 2022-02-10 5:58 pm Purchase | 2022-02-11 | 13G | ARS Pharmaceuticals, Inc. SPRY | Wasatch Advisors LP | 1,775,690 5.100% | 1,775,690 (New Position) | Filing History |
| 2022-02-09 10:24 am Sale | 2022-02-08 | 13G | ARS Pharmaceuticals, Inc. SPRY | FMR LLC | 3,753,737 10.701% | -505,875 (-11.88%) | Filing History |
| 2022-01-27 3:05 pm Sale | 2021-12-13 | 13D | ARS Pharmaceuticals, Inc. SPRY | U.S. Venture Partners XII L.P. | 110,120 0.300% | -2,160,360 (-95.15%) | Filing History |
| 2021-02-16 4:39 pm Purchase | 2020-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY | RA Capital Management, L.P. | 1,742,186 5.000% | 1,742,186 (New Position) | Filing History |
| 2021-02-16 4:01 pm Purchase | 2020-12-31 | 13G | ARS Pharmaceuticals, Inc. SPRY | NEXTECH VI ONCOLOGY SCSP | 1,910,029 5.500% | 1,910,029 (New Position) | Filing History |
| 2021-02-10 09:23 am Purchase | 2021-02-09 | 13G | ARS Pharmaceuticals, Inc. SPRY | FMR LLC | 4,259,612 12.243% | 818,308 (+23.78%) | Filing History |
| 2021-02-08 10:33 am Purchase | 2021-02-05 | 13G | ARS Pharmaceuticals, Inc. SPRY | FMR LLC | 3,441,304 9.891% | 3,441,304 (New Position) | Filing History |